Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo Geerts

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 20, 2018
Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the quantitative nature of neurodegenerative disease therapyStuart Maudsley, Viswanath Devanarayan, Bronwen Martin, et al.
European Journal of Pharmacology|June 7, 2017
Towards the virtual human patient. Quantitative Systems Pharmacology in Alzheimer's diseaseHugo Geerts, Athan Spiros, Patrick Roberts, et al.
Science of Aging Knowledge Environment : SAGE KE|February 11, 2005
Drug discovery in neurodegenerative diseasesHugo Geerts, John Q Trojanowski, Virginia M-Y Lee
Journal of Alzheimer'S Disease : JAD|July 28, 2007
Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathologyJoseph T Coyle, Hugo Geerts, Karin Sorra, et al.
Frontiers in Pharmacology|October 20, 2023
Editorial: Innovative pharmacometric approaches to inform drug development and clinical useMaria Garcia-Cremades, Zinnia P Parra-Guillen, Victor Mangas-Sanjuan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 28, 2023
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseasesHugo Geerts, Silke Bergeler, William W Lytton, et al.
Frontiers in Pharmacology|May 18, 2026
Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology studyHugo Geerts, Shaina M Short, Athena Grant, et al.
Brain Research|February 8, 2005
Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbitsHugo Geerts, Pierre-Olivier Guillaumat, Christopher Grantham, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 22, 2016
Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulationMagali Haas, Diane Stephenson, Klaus Romero, et al.
Plos One|December 20, 2012
Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug responseHugo Geerts, Athan Spiros, Patrick Roberts, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 20, 2018
Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the quantitative nature of neurodegenerative disease therapyStuart Maudsley, Viswanath Devanarayan, Bronwen Martin, et al.
European Journal of Pharmacology|June 7, 2017
Towards the virtual human patient. Quantitative Systems Pharmacology in Alzheimer's diseaseHugo Geerts, Athan Spiros, Patrick Roberts, et al.
Science of Aging Knowledge Environment : SAGE KE|February 11, 2005
Drug discovery in neurodegenerative diseasesHugo Geerts, John Q Trojanowski, Virginia M-Y Lee
Journal of Alzheimer'S Disease : JAD|July 28, 2007
Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathologyJoseph T Coyle, Hugo Geerts, Karin Sorra, et al.
Frontiers in Pharmacology|October 20, 2023
Editorial: Innovative pharmacometric approaches to inform drug development and clinical useMaria Garcia-Cremades, Zinnia P Parra-Guillen, Victor Mangas-Sanjuan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 28, 2023
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseasesHugo Geerts, Silke Bergeler, William W Lytton, et al.
Frontiers in Pharmacology|May 18, 2026
Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology studyHugo Geerts, Shaina M Short, Athena Grant, et al.
Brain Research|February 8, 2005
Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbitsHugo Geerts, Pierre-Olivier Guillaumat, Christopher Grantham, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 22, 2016
Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulationMagali Haas, Diane Stephenson, Klaus Romero, et al.
Plos One|December 20, 2012
Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug responseHugo Geerts, Athan Spiros, Patrick Roberts, et al.
Pageof 8